Inhibitors of cyclin-dependent kinases (CDKs) 4/6 have emerged as a powerful class of
agents with clinical activity in several malignancies. Targeting the cell cycle represents a …

Uncontrolled cell division is the hallmark of cancers. Full understanding of cell cycle
regulation would contribute to promising cancer therapies. In particular, cyclin-dependent …

Inhibition of the cell-cycle kinases CDK4 and CDK6 is now part of the standard treatment in
advanced breast cancer. CDK4/6 inhibitors, however, are not expected to cooperate with …

Background Urothelial carcinoma (UC) is the most common pathological type of bladder
cancer, a malignant tumor. However, an integrated multi-omics analysis of the Chinese UC …

Abstract CDK4/6 inhibitors (CDK4/6i) and oncolytic viruses are promising therapeutic agents
for the treatment of various cancers. As single agents, CDK4/6 inhibitors that are approved …

Simple Summary This review provides an overview of the state of knowledge and general
understanding of CDK inhibitors currently under development or clinically approved, with a …

Abstract Cyclin-dependent kinase 6 (EC 2.7. 11.22) play significant roles in numerous
biological processes and triggers cell cycle events. CDK6 controlled the transcriptional …

Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor
activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6 inhibitor that is approved for …

The JAK-STAT signalling pathway regulates cellular processes like cell division, cell death
and immune regulation. Dysregulation has been identified in solid tumours and STAT3 …

Mutation or promoter hypermethylation of CDKN2A is found in over 90% of pancreatic ductal
adenocarcinomas (PDAC) and leads to loss of function of cell-cycle inhibitors p16 (INK4A) …